Construction of Peptide-Drug Conjugates for Selective Targeting of Malignant Tumor Cells
Eirinaios I Vrettos1, Andreas G Tzakos2
1Department of Chemistry, Laboratory of Organic Chemistry, University of Ioannina, Ioannina, Greece.
Abstract:
Cancer constitutes a major threat to humanity, while its incidence and mortality rates are increasing rapidly worldwide. To tackle cancer, numerous strategies have been exploited, including the development of peptide-drug conjugates (PDCs), which are considered an appealing approach to selectively populate malignant tumors with toxic substances. The general architecture of a PDC usually includes three parts: the tumor-targeting peptide, the cytotoxic drug, and the biodegradable linker. Due to the fact that peptides possess fast renal clearance, affecting the bioavailability of the PDC, a nanodrug formation concept can be exploited to ameliorate this pitfall. Herein, we present methodologies to develop PDCs, along with certain basic principles governing such constructs. In addition, we highlight possible problems that may appear during the synthesis of PDCs, as also solutions to overcome them.
Insights
Peptide-drug conjugates (PDCs) offer targeted cancer therapy by delivering cytotoxic drugs to tumors. Nanodrug strategies enhance PDC bioavailability, overcoming limitations like rapid clearance for improved cancer treatment.
Area of Science:
- Oncology
- Nanomedicine
- Medicinal Chemistry
Background:
- Cancer remains a significant global health challenge with rising incidence and mortality.
- Peptide-drug conjugates (PDCs) are a promising strategy for targeted cancer therapy, delivering cytotoxic agents specifically to tumors.
- Peptide fast renal clearance can limit the bioavailability of PDCs.
Purpose of the Study:
- To present methodologies for developing peptide-drug conjugates (PDCs).
- To outline basic principles for constructing effective PDCs.
- To address challenges and solutions in PDC synthesis.
Main Methods:
- Exploration of peptide-drug conjugate (PDC) design principles.
- Investigation of nanodrug formation strategies to improve peptide bioavailability.
- Analysis of synthetic pathways and potential pitfalls in PDC development.
Main Results:
- Methodologies for PDC development are presented.
- Principles for constructing PDCs are discussed.
- Potential synthetic challenges and their solutions are highlighted.
Conclusions:
- PDCs represent a viable strategy for targeted cancer treatment.
- Nanodrug approaches can enhance PDC efficacy by improving bioavailability.
- Understanding synthetic challenges is crucial for successful PDC development.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:27Tumor Immunotherapy
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...